What’s Baudax Bio Inc. (BXRX)’s Price to Earnings Ratio?


Baudax Bio Inc. (NASDAQ:BXRX) saw an upside of 32.38% to close Tuesday at $4.17 after adding $1.02 on the day. The 5-day average trading volume is 9,670,340 shares of the company’s common stock. It has gained $6.89 in the past week and touched a new high 2 times within the past 5 days. An average of 4,394,390 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,539,401.

BXRX’s 1-month performance is 84.51% or $1.87 on its low of $2.00 reached on 12/28/22. The company’s shares have touched a 52-week low of $1.55 and high of $306.46, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, BXRX has achieved 31.13% or $0.99 and has reached a new high 2 times. However, the current price is down -98.64% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Valuation Metrics

Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 1.40.

Baudax Bio Inc.’s quick ratio for the period ended September 29 was 0.30, with the current ratio over the same period at 0.50. The firm’s gross profit as reported stood at -$1.36 million against revenue of $1.08 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 41.94% to -$29.21 million, while revenue of -$7.53 million was 74.22% off the previous quarter. Analysts expected BXRX to announce -$21.2 per share in earnings in its latest quarter, but it posted -$98.8, representing a -366.00% surprise. EBITDA for the quarter stood at more than -$28.01 million. BXRX stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 37.05 million, with total debt at $8.71 million. Shareholders hold equity totaling $0.5 million.

Let’s look briefly at Baudax Bio Inc. (BXRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 65.62% to suggest the stock is trending Neutral, with historical volatility in this time period at 179.68%.

The stock’s 5-day moving average is $3.37, reflecting a +19.48% or $0.68 change from its current price. BXRX is currently trading +51.64% above its 20-day SMA, -66.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -23.91% and SMA200 by-94.01%.

Stochastic %K and %D was 39.82% and 36.93% and the average true range (ATR) pointed at 0.88. The RSI (14) points at 57.64%, while the 14-day stochastic is at 33.50% with the period’s ATR at 0.84. The stock’s 9-day MACD Oscillator is pointing at 0.14 and 0.15 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Baudax Bio Inc. (NASDAQ: BXRX), JMP Securities launched coverage with a Mkt outperform rating. Analysts offering their rating for BXRX stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate BXRX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.

What is BXRX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $24.00 and a high of $24.00, with their median price target at $24.00. Looking at these predictions, the average price target given by analysts is for Baudax Bio Inc. (BXRX) stock is $24.00.


Please enter your comment!
Please enter your name here